About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of ...
In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), ...
Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies Arcus Biosciences, Inc. (NYSE ...
Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies HAYWARD, Calif.--(BUSINESS ...
One of the critical reasons is Merck’s plan to launch its subcutaneous version of Keytruda (pembro) earlier than previously anticipated, with a new target date of 2025. This accelerated timeline ...
“When [PD-1 inhibitors] first came out, we were like ‘everyone gets pembro,’ no matter the PD-L1 expression level because there was literally nothing else,” Harpreet Singh, former FDA division ...
Panelists discuss the INSEMA trial, comparing no axillary surgery versus axillary sentinel lymph node biopsy (SLNB) in patients with early invasive breast cancer, exploring the implications for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback